Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Retrophin Inc (RTRX)

Retrophin Inc (RTRX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
24.25 -0.11 (-0.45%) 11/18/20 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 24.25 unch (unch) -
Quote Overview for Wed, Nov 18th, 2020
Day Low
24.04
Day High
24.74
Open 24.57
Previous Close 24.36 24.36
Volume 378,900 378,900
Avg Vol 335,225 335,225
Stochastic %K 86.76% 86.76%
Weighted Alpha +75.80 +75.80
5-Day Change +0.25 (+1.04%) +0.25 (+1.04%)
52-Week Range 8.98 - 24.96 8.98 - 24.96
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,238,011
  • Shares Outstanding, K 51,052
  • Annual Sales, $ 175,340 K
  • Annual Income, $ -146,430 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.71
  • Price/Sales 7.09
  • Price/Cash Flow N/A
  • Price/Book 4.10
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.70
  • Most Recent Earnings $-0.26 on 02/24/20
  • Next Earnings Date 11/05/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.44
  • Number of Estimates 4
  • High Estimate -0.35
  • Low Estimate -0.59
  • Prior Year -0.70
  • Growth Rate Est. (year over year) +37.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.52 +24.23%
on 11/02/20
Period Open: 21.89
24.96 -2.84%
on 11/11/20
+2.36 (+10.78%)
since 10/16/20
3-Month
17.22 +40.82%
on 09/24/20
Period Open: 18.43
24.96 -2.84%
on 11/11/20
+5.82 (+31.58%)
since 08/18/20
52-Week
8.98 +170.04%
on 03/18/20
Period Open: 13.02
24.96 -2.84%
on 11/11/20
+11.23 (+86.32%)
since 11/18/19

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal', Cholbam, and Thiola',...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 25.04
1st Resistance Point 24.65
Last Price 24.25
1st Support Level 23.95
2nd Support Level 23.64
3rd Support Level N/A

See More

52-Week High 24.96
Last Price 24.25
Fibonacci 61.8% 18.86
Fibonacci 50% 16.97
Fibonacci 38.2% 15.08
52-Week Low 8.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals